JP2019514358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514358A5 JP2019514358A5 JP2018552822A JP2018552822A JP2019514358A5 JP 2019514358 A5 JP2019514358 A5 JP 2019514358A5 JP 2018552822 A JP2018552822 A JP 2018552822A JP 2018552822 A JP2018552822 A JP 2018552822A JP 2019514358 A5 JP2019514358 A5 JP 2019514358A5
- Authority
- JP
- Japan
- Prior art keywords
- rrs
- vector
- nucleotide sequence
- nucleic acid
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 89
- 125000003729 nucleotide group Chemical group 0.000 claims description 89
- 102100030355 Host cell factor 1 Human genes 0.000 claims description 64
- 239000003550 marker Substances 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 102000025171 antigen binding proteins Human genes 0.000 claims description 16
- 108091000831 antigen binding proteins Proteins 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 208000005229 Autosomal recessive Robinow syndrome Diseases 0.000 claims description 7
- 238000001945 resonance Rayleigh scattering spectroscopy Methods 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 6
- 108010091086 Recombinases Proteins 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 37
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137796A JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 | |
| US62/325,385 | 2016-04-20 | ||
| PCT/US2017/028552 WO2017184831A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137796A Division JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514358A JP2019514358A (ja) | 2019-06-06 |
| JP2019514358A5 true JP2019514358A5 (enExample) | 2020-05-28 |
| JP7134868B2 JP7134868B2 (ja) | 2022-09-12 |
Family
ID=58701850
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552822A Active JP7134868B2 (ja) | 2016-04-20 | 2017-04-20 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2022137796A Active JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A Active JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137796A Active JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A Active JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530277B2 (enExample) |
| EP (1) | EP3445780A1 (enExample) |
| JP (3) | JP7134868B2 (enExample) |
| KR (2) | KR102474757B1 (enExample) |
| CN (2) | CN109071633B (enExample) |
| AR (1) | AR108295A1 (enExample) |
| AU (2) | AU2017253240B2 (enExample) |
| BR (1) | BR112018071285A2 (enExample) |
| CA (1) | CA3015371A1 (enExample) |
| EA (1) | EA201892137A1 (enExample) |
| IL (2) | IL262268B2 (enExample) |
| MX (2) | MX2018012866A (enExample) |
| SG (2) | SG11201807881VA (enExample) |
| TW (1) | TW201803981A (enExample) |
| WO (1) | WO2017184831A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| KR102559149B1 (ko) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| EP3980544A1 (en) * | 2018-12-21 | 2022-04-13 | F. Hoffmann-La Roche AG | Targeted integration of nucleic acids |
| CN113661173B (zh) | 2019-03-29 | 2024-10-01 | 豪夫迈·罗氏有限公司 | 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法 |
| SG11202110076PA (en) | 2019-04-02 | 2021-10-28 | Chugai Pharmaceutical Co Ltd | Method of introducing target-specific foreign gene |
| KR20220024637A (ko) | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법 |
| AU2020294879A1 (en) * | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| WO2020254351A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140297A1 (en) * | 2019-06-19 | 2020-12-24 | Simon Auslaender | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
| AU2020297940A1 (en) * | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| EP3990649A1 (en) * | 2019-06-26 | 2022-05-04 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| EP4087925A2 (en) * | 2020-01-10 | 2022-11-16 | F. Hoffmann-La Roche AG | Method for the assembly of large nucleic acids from short fragments |
| CN119731330A (zh) * | 2021-12-22 | 2025-03-28 | 基因泰克公司 | 多载体重组酶介导的盒式交换 |
| CN121794393A (zh) | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| WO2025115876A1 (ja) | 2023-11-29 | 2025-06-05 | 富士フイルム株式会社 | 細胞の作出方法、細胞及びタンパク質の製造方法 |
| KR20260103112A (ko) | 2023-11-29 | 2026-07-02 | 후지필름 가부시키가이샤 | 탐색 방법, 세포의 작출 방법, 세포의 선별 방법, 세포 및 세포 생산물의 제조 방법 |
| WO2026132369A1 (en) | 2024-12-22 | 2026-06-25 | F. Hoffmann-La Roche Ag | Method for the generation of a bivalent, bispecific fragment antigen binding expressing mammalian cells |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| JP2004516015A (ja) | 2000-08-07 | 2004-06-03 | ジェンセット | 精神分裂病関連遺伝子およびタンパク質 |
| GB0209884D0 (en) | 2002-04-30 | 2002-06-05 | Ares Trading Sa | Proteins |
| CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US20050019925A1 (en) | 2002-11-14 | 2005-01-27 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| DK2150617T3 (en) * | 2007-06-04 | 2015-01-12 | Regeneron Pharma | Regions with increased expression and stability |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| DK2808393T3 (en) | 2009-06-02 | 2018-03-12 | Regeneron Pharma | Cells insufficient for fucosylation |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| CN102712696A (zh) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI864338B (zh) | 2012-11-14 | 2024-12-01 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3209785B1 (en) | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
-
2017
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
- 2022-11-10 US US18/054,350 patent/US12503520B2/en active Active
-
2023
- 2023-12-04 IL IL309065A patent/IL309065B2/en unknown
-
2024
- 2024-08-26 JP JP2024144352A patent/JP7789143B2/ja active Active
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250101080A1 (en) | Chimeric antigen receptors and uses thereof | |
| JP2019515666A5 (enExample) | ||
| CN106011104B (zh) | 利用拆分Cas系统进行基因编辑和表达调控方法 | |
| ES2909150T3 (es) | Composiciones y colecciones que comprenden receptores de células T recombinantes y procedimientos de uso de receptores de células t recombinantes | |
| US10323077B2 (en) | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer | |
| Howitt et al. | Adenovirus interaction with its cellular receptor CAR | |
| JP2021534770A5 (enExample) | ||
| JP2022534282A5 (enExample) | ||
| CN109071633A (zh) | 基于使用表达增强性基因座来制备抗体的组合物和方法 | |
| CN113347993A (zh) | 突变牛痘病毒及其用途 | |
| CN111315761A (zh) | 用于选择性转导靶细胞的基于衔接子的逆转录病毒载体系统 | |
| JP2018533963A5 (enExample) | ||
| CN110996658B (zh) | 包含人源化asgr1基因座的非人动物 | |
| KR20170012324A (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
| CN105177031A (zh) | 嵌合抗原受体修饰的t细胞及其用途 | |
| CN106117354A (zh) | 一种全人源抗CD47的全分子IgG抗体及其应用 | |
| CN111892661B (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP2014517690A5 (enExample) | ||
| EP2663643A1 (en) | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scfv) | |
| CN104745596B (zh) | 靶向肝癌细胞的细胞制备物 | |
| JP2022502081A (ja) | 遺伝子操作された微生物ならびにそれを作製および使用する方法 | |
| CN109280674B (zh) | 一种筛选抗体的非人模式动物的构建方法及其应用 | |
| CN105802975A (zh) | 靶向her2阳性肿瘤的细胞制备物及其用途 | |
| CN114539429B (zh) | 融合蛋白组合物及其应用 | |
| JP2005514957A5 (enExample) |